| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/19/2009 | US20090076033 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/19/2009 | US20090076026 Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects of dry-mouth and constipation; biphenyl carbamate derivatives; biphenyl-2-ylcarbamic acid 1-(3-(3-[3-(4-hydroxybenzylamino)propyl]-2-oxoimidazolidin-1-yl)propyl)piperidin-4-yl ester |
| 03/19/2009 | US20090076021 Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease |
| 03/19/2009 | US20090076018 Deuterium-enriched ranolazine |
| 03/19/2009 | US20090075993 N-[3-(1 -piperidinyl)propoxy]-pyridin-1-oxide-3-carboxamidine ; increasing vaso-relaxation of a vessel associated with endothelial cells |
| 03/19/2009 | US20090075985 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 03/19/2009 | US20090075981 INHIBITORS OF p38 |
| 03/19/2009 | US20090075979 CETP Inhibitors |
| 03/19/2009 | US20090075975 Arylsulfonamides and uses related thereto |
| 03/19/2009 | US20090075968 CETP inhibitors |
| 03/19/2009 | US20090075956 Genetic Risk Assessment in Heart Failure: Impact of the Genetic Variation of NOS3 |
| 03/19/2009 | US20090075949 such as dabigatran etexilate, rivaroxaban, Ximelagatran, bivalirudin, Apixaban |
| 03/19/2009 | US20090075933 Cytocompatible alginate gels |
| 03/19/2009 | US20090075924 antisense therapy; for diagnosis and treatment of atherosclerosis, hypercholesterolemia, or coronary artery disease |
| 03/19/2009 | US20090075912 Use of Timosaponin BII in the Preparation Of A Medicament or Product for the Prevention and Treatment of Stroke |
| 03/19/2009 | US20090075901 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist |
| 03/19/2009 | US20090075896 hypotensive polypeptide in dairy product food; milk proteins as inhibitor of angiotensin I-converting enzyme; treating cardiovascular disease |
| 03/19/2009 | US20090075888 Cardiovascular and Brain Cell Therapy Using Intracellular Ryanodine Receptor Modulation by the Estrogen Receptor Beta |
| 03/19/2009 | US20090075881 Fibrin gel for controlled release of pdgf and uses thereof |
| 03/19/2009 | US20090075872 Methods and means |
| 03/19/2009 | US20090075866 Reducing hypotensive events experienced by normovolemic subject during surgery while under general anesthesia via modified hemoglobin |
| 03/19/2009 | US20090075864 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
| 03/19/2009 | US20090075373 Neural progenitor cells derived from embryonic stem cells |
| 03/19/2009 | US20090074890 Substituted Triazoles as Sodium Channel Blockers |
| 03/19/2009 | US20090074859 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 03/19/2009 | US20090074830 Anti-angiogenic compositions and methods of use |
| 03/19/2009 | US20090074828 Poly(amino acid) targeting moieties |
| 03/19/2009 | US20090074788 Antibody Against Periostin, and a Pharmaceutical Composition comprising it for Preventing or Treating a Disease in which Periostin is Involved |
| 03/19/2009 | US20090074744 Use of collagenase to facilitate guide wire crossing in total arterial occlusions |
| 03/19/2009 | US20090074731 Method of isolation and use of cells derived from first trimester umbilical cord tissue |
| 03/19/2009 | US20090074728 Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
| 03/19/2009 | US20090074722 Products and methods for treating PTP lar diseases |
| 03/19/2009 | US20090074669 PNMT as a novel marker for progenitor cells |
| 03/19/2009 | US20090074663 Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof |
| 03/19/2009 | DE102007044032A1 New substituted heteroaryl compounds are hypoxia-inducible factor prolyl-4-hydroxylase inhibitors useful to treat and/or prevent e.g. circulatory heart diseases, heart failure, anemia, chronic kidney diseases and renal failure |
| 03/19/2009 | CA2731204A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2704726A1 Use of a defensin peptide as a therapeutic agent |
| 03/19/2009 | CA2699414A1 Treatment of vasomotor symptoms |
| 03/19/2009 | CA2699236A1 Cell growth method and pharmaceutical preparation for tissue repair and regeneration |
| 03/19/2009 | CA2699222A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699215A1 (d-leu7 ) -histrelin as a therapeutic agent |
| 03/19/2009 | CA2699167A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699026A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699020A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699012A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699010A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699008A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2699006A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698992A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698985A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698984A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698981A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698980A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698978A1 Use of human neuropeptide af as a therapeutic agent |
| 03/19/2009 | CA2698977A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent |
| 03/19/2009 | CA2698976A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698974A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698971A1 Use of urodilatin as a therapeutic agent |
| 03/19/2009 | CA2698966A1 Use of fertirelin and delta-endorphin as therapeutic agents |
| 03/19/2009 | CA2698963A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698912A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698855A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698852A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698833A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698831A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698828A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698824A1 Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
| 03/19/2009 | CA2698822A1 Minigastrin as a therapeutic agent |
| 03/19/2009 | CA2698821A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698786A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698783A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698778A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698770A1 Use of secretin and optionally urodilatin as a therapeutic agents |
| 03/19/2009 | CA2698759A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698754A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698748A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698745A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698693A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698691A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698682A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698666A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | CA2698471A1 Substituted 6-phenylnicotinic acids and the use thereof |
| 03/18/2009 | EP2036905A1 Pyridylisoxazole derivative |
| 03/18/2009 | EP2036902A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain |
| 03/18/2009 | EP2036896A1 Cyclic amine compound |
| 03/18/2009 | EP2036895A1 Hsp90 inhibitor |
| 03/18/2009 | EP2036892A1 1,2,4,5-tetrahydro-3H-benzazepine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 03/18/2009 | EP2036891A2 Isoquinoline inhibitors of P38 |
| 03/18/2009 | EP2036890A1 Crystalline form (i) of lercanidipine hydrochloride |
| 03/18/2009 | EP2036887A1 Novel 6-5 bicycic heterocyclic derivative and medical use thereof |
| 03/18/2009 | EP2036571A1 Use of G-CSF for treating strokes |
| 03/18/2009 | EP2036570A1 Means and methods for influencing platelet-collagen interaction |
| 03/18/2009 | EP2036567A2 Modulation of the P2Y2 receptor pathway |
| 03/18/2009 | EP2036560A1 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione for the treatment of benign prostatic hypertrophy |
| 03/18/2009 | EP2035420A2 Kv1.5 potassium channel inhibitors |
| 03/18/2009 | EP2035419A1 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists |
| 03/18/2009 | EP2035409A1 Benzimidazole derivatives which are to be used as anatgonist for the cb1-receptor |
| 03/18/2009 | EP2035392A1 Imidazole kv1. 5 potassium channel inhibitors |
| 03/18/2009 | EP2035386A1 Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
| 03/18/2009 | EP2035369A1 Therapeutic compounds |